Source: International Congress 2018 – Pulmonary hypertension: therapy
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. McLaughlin (Ann Arbor, United States of America), K. Chin (Dallas, United States of America), H. Farber (Boston, United States of America), K. Highland (Cleveland, United States of America), A. Hemnes (Nashville, United States of America), M. Chakinala (St. Louis, United States of America), C. Zhao (South San Francisco, United States of America), M. Keating (South San Francisco, United States of America), N. Kim (San Diego, United States of America). Interim analysis of pulmonary arterial hypertension (PAH)-targeted background therapy in SPHERE (SelexiPag: tHe usErs dRug rEgistry). 3043

Member's Comments

No comment yet.

Related content which might interest you: Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 An international survey of current pulmonary arterial hypertension (PAH) management Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) Source: Eur Respir J 2015; 45: 1303-1313 Year: 2015 Upfront combination therapy in the treatment of scleroderma-associated pulmonary arterial hypertension: Results of an open label trial Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 An evaluation of outcomes for patients with pulmonary hypertension (PH) incorporated into a standard UK pulmonary rehabilitation (PR) programme Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 REVEAL: a contemporary US pulmonary arterial hypertension registry Source: Eur Respir Rev 2012; 21: 8-18 Year: 2012 Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 A USA-based registry for pulmonary arterial hypertension: 1982 2006 Source: Eur Respir J 2007; 30: 1103-1110 Year: 2007 Cambridge pulmonary hypertension outcomes review (CAMPHOR) utility assessment in pulmonary hypertension (PH) patients Source: Annual Congress 2007 - Pulmonary hypertension in the clinic Year: 2007 Effects of pulmonary rehabilitation (PR) in idiopathic pulmonary arterial hypertension (PAHI) Source: Annual Congress 2013 –The latest insights in pulmonary rehabilitation (part 2) Year: 2013 Patient perspectives on exercise training in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 LTI-201: Evaluation of the hemodynamics and safety of inhaled LIQ861 (treprostinil) in pulmonary arterial hypertension (WHO Group 1) patients Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 General and standard therapy of pulmonary arterial hypertension Source: International Congress 2017 – Russian Programme 2017 Year: 2017